Clinical trial · Interventional
Clinical Observation of Recombinant Human Growth Hormone Injection Assisted IVF-ET in the Treatment of PCOS
Clinical Observation of Recombinant Human Growth Hormone Injection Assisted in Vitro Fertilization and Embryo Transfer (IVF-ET) in the Treatment of Polycystic Ovary Syndrome (PCOS)
NCT02801565CI-TRIAL-00024914unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Observe validity of Recombinant Human Growth Hormone Injection assisted in IVF-ET (in vitro fertilization and embryo transfer) treatment of PCOS (polycystic ovary syndrome) patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Polycystic Ovary Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Conventional controlled ovarian stimulation proctol | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- GH AQ
- description
- Controlled ovarian stimulation in the middle of the corpus (D21 days) of the previous menstrual cycle to use recombinant Human Growth Hormone Injection（rhGH） Injection 15IU/5mg/3mL/cartridge, 5IU per day, Subcutaneous injection after 20:00 until the HCG trigger day.
- interventionNames
- Drug: Conventional controlled ovarian stimulation proctol
Primary outcomes (2)
- measure
- Clinical pregnancy rate
- timeFrame
- One year
- measure
- Number of fertilized oocytes
- timeFrame
- One year
Secondary outcomes (3)
- measure
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 25 Years
- Maximum age
- 35 Years
Show eligibility criteria text
Inclusion Criteria: * Age between 25 and 35 years old, married female and infertile. * BMI≥25kg/m2. * Diagnosed as PCOS. * No obvious chronic organic diseases, such as liver, kidney, heart, lung, thyroid, adrenal disease. * Subjects do not take part in other clinical trial study within 3 months. * The subjects sign the informed consent form. Exclusion Criteria: * BMI\<25kg/m2. * Hyperprolactinemia and congenital adrenal cortical hyperplasia. * Diabetes, thyroid function hyperthyroidism, thyroid dysfunction, cushing's syndrome. * Pelvic and peritoneal tumor and tumor secreting hyperandrogenism. * Severe acute and chronic liver and kidney disease, such as liver cirrhosis, acute and chronic renal failure, hepatitis B virus activity. * Liver and kidney dysfunction, AST/ALT is 2.5 times higher than the normal limit, the serum of creatinine is 2 times higher than the normal level. * Diseases affecting outcome of IVF pregnancy, eg, hydrosalpinx, hysteromyoma\>4 cm, adenomyosis, endometriosis, endometrial cyst of ovary, unilateral ovary, tuberculosis of reproductive system. * Allergic to E. coli. expression product and its excipients. * Being involved in other drug clinical researchers. * The researchers consider who is not suitable for the group.
References
Publications (0)
Data not yet available
No reference posted for this study.